



10100 Dr. M.L. King Jr. St. N.
St. Petersburg, FL 33716
Phone: (727) 568-1213

PRESS RELEASE

Contact: Thomas McLain
Claro Scientific, LLC
(561) 789-8064

thomas.mclain@clarosci.com

Claro Scientific Receives Notice of Allowance for Blood Culture Patent

St. Petersburg, FL--(April 15, 2011) — Claro Scientific today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for Claro's claims for the use of real-time monitoring of blood cultures for pathogen detection entitled "Detecting Microorganisms in Blood Utilizing Physical and Chemical Changes in Blood."

The approach provided in this patent exploits hemoglobin as an intrinsic indicator of the presence of infectious organisms in blood culture. This method overcomes key challenges for blood culture systems in use today. The methodology shares key advantages common to all of Claro's medical diagnostic applications. It eliminates the need for specialized reagents or indicators; the result is determined quantitatively and is not dependent upon a highly trained laboratory technician; results are available much faster than with other methods (Claro estimates a 30-50% improvement over methods used in the hospital laboratory today); and the same method can be adapted to monitor other health factors including the response of an infectious agent to the prescribed therapy.

"This important advance will be developed to improve the speed and accuracy of diagnosing infections in blood and blood culture samples," stated Luis Garcia-Rubio, Claro's President and Chief Scientific Officer. "By providing actionable information about blood stream infections faster, healthcare workers can deliver the best treatment to an individual patient. This can result in shorter hospital stays, lower treatment costs and improved patient outcomes."

This allowance further expands Claro's extensive patent portfolio which includes exclusive rights to eleven other patents pertaining to optical evaluation of biological systems using Claro's innovative hardware configurations and interpretation models. The Company is continuing to expand its intellectual property with new patents related to systems, methods and applications for medical diagnostics, protein analysis and other biotechnology related applications.

"When combined with the results of recent clinical studies, this new intellectual property further substantiates the value of Claro's innovative approach to medical diagnostics using the SpectraWave system and SISTERS' database of optical profiles," said Tom McLain, Claro's Chief Executive Officer. "The same core technology can be used for the analysis of the causes of disease and other health factors using small samples of bodily fluids such as blood and urine. Claro's goal is to provide the information healthcare workers need in real time to treat conditions and save lives, by bringing laboratory testing to the patient. The novel advances that make this major improvement in healthcare delivery possible are being secured through the combination of patents, know-how and the expansion of Claro's proprietary database of optical profiles for pathogens, disease related conditions and general health markers."

About Claro Scientific, LLC

Claro Scientific is developing SpectraWave™, an innovative, reagentless diagnostic system platform using its patented multidimensional optical profiling technology. Claro's proprietary software and database system, SISTERS™, interprets this data to deliver highly precise, detailed and quantitative information about the composition and character of biologic and non-biologic samples in less than 5 minutes. SpectraWave and SISTERS have significant competitive advantages in several commercial markets including protein characterization, cellular analysis, biotechnology process development and research, medical diagnostics, personalized health monitoring, blood banking, biodefense, environmental monitoring, agriculture, food safety and veterinary medicine. Each commercial application leverages a core hardware platform, application software and optical profile databases.

For further information, please visit: www.clarosci.com.

Forward Looking Information

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Claro's plans, objectives, expectations and intentions. These forward-looking statements are based on Claro's current expectations. Claro notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Claro's ability to protect and promote its proprietary technology; (2) Claro's lack of a track record of successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Claro will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Claro will successfully license or otherwise successfully partner with third parties to commercialize its future products. All information in this press release is as of the date of this report, and Claro expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Claro's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

###